Using Real World Data to Close the Rare Disease Gap

7,000. That’s the estimated number of distinct types of rare and genetic diseases affecting more than 400 million people around the world. Yet 95% of rare diseases lack an FDA-approved product for treatment.1 Even with the Orphan Drug Act, there are many daunting barriers that stand between researchers and results. Read how de-identified, real-world data (RWD) – featuring claims and electronic health record (EHR) data – creates a remarkable opportunity to fill the data divide, power development and demonstrate the effectiveness of treatment options. Download the whitepaper here.